PLK1 as an oncology target: current status and future potential

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Polo-like kinases (PLKs) are established targets in oncology.
• Recent advancements have yielded potent PLK inhibitors.
• Understanding PLK roles in tumor molecular defects is crucial.

Purpose of the Study:

• To report progress in clinical validation of PLKs as antitumor drug targets.
• To elucidate synergistic roles of PLKs with other molecular defects in tumors.
• To discuss strategies for developing isoform-specific PLK inhibitors.

Main Methods:

• Review of recent clinical validation studies for PLK inhibitors.
• Analysis of synergistic roles of PLKs in tumor contexts.
• Exploration of Polo-box domain as a target for specific inhibition.

Main Results:

• PLKs are validated as promising antitumor drug targets.
• Synergistic roles of PLKs with molecular defects are increasingly understood.
• Potential drawbacks of non-isoform selective inhibitors are identified.

Conclusions:

• PLK inhibitors represent a significant therapeutic avenue in oncology.
• Targeting the Polo-box domain offers a strategy for achieving PLK1 specificity.
• Further development of isoform-selective PLK inhibitors is warranted.